My Hemophilia Life

01/12/2023

Hemophilia Breakthrough: New Gene Therapies Could Offer a Cure
Researchers are developing new gene therapies for hemophilia A and B that are more efficient and less expensive than current therapies: A new hope for a cure Hemophilia A and B are genetic bleeding disorders that affect males. They are caused by mutations in the genes that code for factor VIII and factor IX, respectively, […]

With continued progress, we can hope to one day find a cure for hemophilia A and B and improve the lives of everyone affected by these conditions.

29/11/2023

Researchers create novel hemophilia B gene treatment
Researchers create novel hemophilia B gene treatment, offering a fresh prospect for recovery. Males are affected by an uncommon inherited bleeding condition called hemophilia B. A mutation in the gene that codes for factor IX, a clotting factor necessary for healthy blood coagulation, is the cause of it. Those who have hemophilia B are susceptible […]

To ascertain the safety and effectiveness of gene therapy in people, further research is required as it is still in its early phases of development.

29/11/2023

FDA grants orphan drug status to TI-168 for hemophilia A inhibitors
Baudax Bio‘s investigational regulatory T-cell therapy, TI-168, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A with inhibitors. Orphan drug status is granted to therapies addressing rare conditions affecting fewer than 200,000 people in the U.S. This designation offers various benefits, including tax credits, clinical […]

Baudax Bio's investigational regulatory T-cell therapy, TI-168, has received orphan drug designation from FDA for the treatment of hemophilia A with inhibitors.

26/11/2023

The FDA approves the use of a plasma product to track FVIII activity
The FDA in the United States has approved CRYOcheck Factor VIII Deficient Plasma with VWF, a produced plasma product from Precision BioLogic, for use in laboratories. Utilizing blood samples, this product can be used to identify factor VIII (FVIII) insufficiency. Normal blood coagulation requires the clotting factor FVIII. Due to an FVIII deficiency, hemophilia A […]

In the US, CRYOcheck Factor VIII Deficient Plasma with VWF is currently accessible in laboratories. In the upcoming months, it will extensively accessible.

17/11/2023

Can you live a normal life with hemophilia?
A bleeding ailment known as hemophilia affects more than 400,000 people globally. It is brought on by a lack of one of the proteins called clotting factors, which aid in blood clotting. People who have hemophilia are therefore susceptible to severe bleeding, which may be fatal. More than half of hemophiliac patients conceal their symptoms, […]

A bleeding ailment known as hemophilia affects more than 400,000 people globally. It is brought on by a lack of one of the proteins called clotting factors, which aid in blood clotting. People who have hemophilia are therefore susceptible to severe bleeding, which may be fatal. More than half of…

25/10/2023

Socio-economic problems of hemophilia
Hemophilia is a rare congenital bleeding disease caused by an X chromosome-linked deficiency in coagulation factors 8 in hemophilia A or factors 9 in hemophilia B. This is a rare disorder and is characterized by spontaneous and potentially life-threatening bleeding episodes. It is a life disorder associated with physical, emotional, economic, and social problems for […]

Patients with hemophilia are affected in their personal as well as professional lives. Especially the ones with inhibitors face more difficulties in managing their life.

21/10/2023

The Impact of Factor 8 Deficiency on Your Daily Life: Coping Strategies and Support
Welcome to our blog on “The Impact of Factor 8 Deficiency on Your Daily Life: Coping Strategies and Support.” Living with factor 8 deficiency can be challenging, but this condition doesn’t define you. In this empowering article, we will explore practical coping strategies and highlight the importance of finding support from others facing similar challenges. […]

Welcome to our blog on "The Impact of Factor 8 Deficiency on Your Daily Life: Coping Strategies and Support." Living with factor 8 deficiency can be challenging, but this condition doesn't define you. In this empowering article, we will explore practical coping strategies and highlight the importanc...

01/01/2023

May the new year bring you peace, joy, and happiness. Happy New Year!

25/12/2022

Wishing you all the happiness your holiday can hold. Merry Christmas!

23/12/2022

Christmas season has always been stressful for me. I live in Florida, but my family lives in the arctic tundra of Illinois and Wisconsin. I can’t understand why my mom and I travel north instead of having everyone come to us in sunny Florida, but as I often say, “It is what it is.” As I write this, in a few days we’ll be heading north, even though a blizzard threatens to derail our plans....

23/12/2022

A committee of the European Medicines Agency (EMA) has issued a positive opinion recommending the one-time gene therapy etranacogene dezaparvovec be granted conditional marketing authorization to treat appropriate adults with hemophilia B. The recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) will now be reviewed by the European Commission, which will issue a final decision that applies to all EU member states, as well as Iceland, Liechtenstein, and Norway…...

A committee of the European Medicines Agency (EMA) has issued a positive opinion recommending the one-time gene therapy etranacogene dezaparvovec be granted conditional marketing authorization to treat appropriate adults with hemophilia B. The recommendation from the EMA’s Committee for Medicinal ...

22/12/2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Hemlibra’s (emicizumab) approval be expanded to include people with moderate hemophilia A without inhibitors. “We’re very pleased that the CHMP’s recommendation brings us closer to potentially transforming the day-to-day lives of people in the EU living with moderate hemophilia A,” said Levi Garraway, MD, PhD, Roche’s chief medical officer and head of global product development, in a…...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Hemlibra’s (emicizumab) approval be expanded to include people with moderate hemophilia A without inhibitors. “We’re very pleased that the CHMP’s recommendation brings us closer to potenti...